ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near London, England, GBR:

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer...

Enrolling
Locally Advanced Breast Cancer
HER2-positive Breast Cancer
Drug: Avelumab
Drug: Palbociclib

Phase 1

Royal Marsden NHS Foundation Trust

London, United Kingdom and 6 other locations

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

London, United Kingdom and 31 other locations

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer...

Active, not recruiting
Gastric Cancer
Lobular Breast Carcinoma
Drug: Crizotinib Oral Capsule [Xalkori]
Drug: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

Phase 2

Royal Marsden NHS Foundation Trust

London, United Kingdom and 4 other locations

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer

PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patien...

Enrolling
Breast Neoplasm
Drug: AZD6738
Drug: Durvalumab

Phase 2

Institute of Cancer Research, United Kingdom

London, United Kingdom and 8 other locations

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC (BARBICAN)

non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Doxorubicin
Drug: Ipatasertib

Phase 2

Queen Mary University of London

London, United Kingdom

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

London, United Kingdom and 199 other locations

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER)

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement ...

Enrolling
Breast Cancer
Drug: Paclitaxel and Carboplatin
Drug: Olaparib

Phase 2, Phase 3

NHS Foundation Trust
NHS Foundation Trust

London, United Kingdom and 29 other locations

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple...

Enrolling
Locally Advanced Breast Cancer
Metastatic Triple Negative Breast Cancers
Drug: BNT327 Equivalent Q3W Dose
Drug: BNT327 Dose Level 1 (DL2)

Phase 2

BioNTech
BioNTech

London, United Kingdom and 35 other locations

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

mg twice per day. Capivasertib or placebo could be interrupted for up to 4 weeks for toxicity.Tumor assessments included computed tomograph...

Active, not recruiting
Metastatic Breast Cancer
Drug: AZD5363
Drug: Paclitaxel

Phase 2

Queen Mary University of London

London, United Kingdom and 45 other locations

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

London, United Kingdom and 228 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems